3 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 79 points (-0.5%) at 16,635 as of Friday, Aug. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,072 issues advancing vs. 1,895 declining with 174 unchanged.

The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 1.1%, Abbott Laboratories ( ABT), down 1.0%, Sanofi ( SNY), down 0.8%, Novartis ( NVS), down 0.8% and GlaxoSmithKline ( GSK), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Merck ( MRK) is one of the companies pushing the Drugs industry lower today. As of noon trading, Merck is down $0.36 (-0.6%) to $58.42 on average volume. Thus far, 4.5 million shares of Merck exchanged hands as compared to its average daily volume of 8.2 million shares. The stock has ranged in price between $58.03-$59.00 after having opened the day at $58.80 as compared to the previous trading day's close of $58.78.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $166.9 billion and is part of the health care sector. Shares are up 15.6% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AbbVie ( ABBV) is down $0.31 (-0.6%) to $53.88 on average volume. Thus far, 6.2 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.8 million shares. The stock has ranged in price between $53.67-$54.58 after having opened the day at $54.34 as compared to the previous trading day's close of $54.19.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $85.3 billion and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.18 (-0.6%) to $28.55 on average volume. Thus far, 11.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.2 million shares. The stock has ranged in price between $28.41-$28.90 after having opened the day at $28.86 as compared to the previous trading day's close of $28.73.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $178.9 billion and is part of the health care sector. Shares are down 7.9% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. Among the primary strengths of the company is its expanding profit margins over time. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists